Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...

Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Novartis AG ( VTX:NOVN ) has announced that it will be increasing its dividend from last year's comparable payment ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The mRNA cancer therapeutics market was valued at USD 13.23 ...

Novartis (NVS) shareholders agreed to the board of directors’ recommendations for all proposed resolutions at the company’s Annual General ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

ZURICH, March 6 (Reuters) - Novartis (NOVN.S), opens new tab is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's ...